At the IGTP TODAY
A study led by researchers from the Resistance, Chemotherapy and Predictive Biomarkers group at the IGTP, published in Clinical and Translational Medicine, provides new evidence on how to improve the efficacy of one of the most widely used chemotherapy combinations in clinical practice for the treatment of colorectal cancer: 5-fluorouracil and irinotecan (FUIRI).
We look back at the year's most significant news stories, showcasing the dedication and collaboration that define IGTP.
Early diagnosis can help prevent serious complications, reduce hospital admissions and minimise the impact of disease onset in children and adolescents
_1766478647.jpeg)
Researchers from the B·ARGO at IGTP and ICO have conducted a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer, published in the journal BBA Reviews on Cancer.
A study led by IGTP researchers shows that, in a laboratory model, delafloxacin inhibits the intracellular replication of Legionella more effectively than a current standard treatment, supporting its potential therapeutic value and the need for future clinical studies.
Work-related factors play a significant and independent role in the risk of developing Long-COVID, shows a new study based on the COVICAT cohort and led by ISGlobal, in collaboration with the University of Turin and the IGTP. The findings, published in BMJ Occupational & Environmental Medicine, highlight that a substantial share of Long-COVID could be prevented through targeted workplace measures and policies.
Researchers at IGTP have published an article analysing the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells to address kidney injury, reviewing current evidence on how these vesicles can interact with renal tubular epithelial cells.
A team of researchers from IGTP and ICO has studied alterations in the KRAS gene in colorectal cancer by combining genomic analyses with a systematic review of targeted compounds and clinical trials. Their findings, published in the journal npj Precision Oncology, provide and updated overview to guide future advances in this cancer's treatment.
A research team has created the first humanised cellular model to study GATA2 deficiency, a rare genetic disorder that predisposes individuals to severe blood conditions such as myelodysplastic syndrome and leukaemia. The study shows that, although the initial GATA2 mutation weakens haematopoietic stem cells, it is additional mutations -particularly in the SETBP1 gene- that drive disease progression.
A new study provides a powerful way to study infections in environments that closely mimic human organs. The strategy, tested in a bone-marrow-on-chip model, was developed by researchers from ISGlobal, IGTP, I3S at Porto University, and IN2UB, as part of the HIDDENVIVAX project, funded by "la Caixa" Foundation.
_1763369329.JPG)